Recently, Usynova Pharmaceuticals Ltd. announced the completion of Series A financing of over RMB 200 million.

This round of financing is led by Shenzhen Share Capital, followed by Zhangjiang Haoheng and Yingke capital. The original shareholders continue to participate in this round of investment.

The raised funds will be used to conduct and accelerate domestic and international clinical trials for UA007 and UA021, the development of small molecule drugs for multiple new targets and the development of specific dual antibody drugs.

Mr. Huang Fanzhi, Co-Founder of Share Capital and Managing Partner of Healthcare Fund, said, 

"We are honored to participate in the Series A financing of Usynova. Usynova has established a relatively mature R&D team equipped with complementary expertise and resources, and has broad market development prospects, focusing on next-generation oncology and autoimmune fields. The project features gradient propulsion, with differentiated indications and R & D sustainability. So we are looking forward to the sustained and rapid development of Usynova in the later stage.

Mr. Wang Wenjie, Deputy General Manager of ZhangJiang Haoheng, said, “The team of Usynova has many years of experience in the development of new drugs at home and abroad, and has laid out both large molecule and small molecule pipelines for specific disease spectrums, forming a differentiated layout, and the products are global market-oriented. Zhangjiang Suifeng Fund managed by Zhangjiang Haoheng is a science and technology innovation sub-fund subordinate to Pudong Kechuang master fund. Zhangjiang High Tech serves as the cornerstone investor and will fully support Usynova’s entrepreneurship and development in Zhangjiang Science City.”

Dr. Li Jinsong, Dr. Hu Tao and Dr. Peng Shengbin, the three co-founders of Usynova, thanked the investors for their recognition and support of the company’s team and pipeline. Chairman Li Jinsong said, “We thank our investors for their recognition of the company's philosophy and team, and our goal is to become a first-class innovative drug development company; in the future, we will focus on establishing an efficient translational medicine R&D system in three areas: international markets, organizational structure, cost and efficiency, and developing cost-controllable innovative drugs for global main variety markets.”

About Usynova

Usynova is an innovative drug company dedicated to First-in-class/Best-in-class drug development, focusing on cancer and autoimmune diseases, and pursuing novel and difficult targets and key oncogenes, with a pipeline of small molecule targeted drugs, recombinant proteins and monoclonal/dual-antibody drugs. The company’s core team has served as senior executives in multinational pharmaceutical companies and leading domestic CROs, and has extensive experience in the field of innovative drug development. At present, in terms of UA007 project, the company has carried out a clinical phase II (prevention and treatment of CID) and a clinical phase I study (treatment of acute gout) in China. UA021, a small molecule targeted drug for autoimmune diseases, is in the IND enabling phase and is expected to be in global clinical trials in 2022.

About Share Capital

Established in Shenzhen in 2007, Share Capital has invested in over 200 companies and currently manages over RMB 8 billion capital. Share Capital has been investing in the healthcare sector since 2010, focusing on four major areas: biotechnology, new drug development, new medical services and cutting-edge medical devices, taking precision medicine as the main line of investment, benchmarking global R&D heights and adapting to emerging domestic market demands. Currently, it manages four healthcare theme funds and has an independent professional healthcare investment team of 12 people with rich investment experience and profound professional background, and has invested in over 80 healthcare projects with a total healthcare fund size of nearly RMB 4.5 billion. Its major investment cases include: BGI Genomics (300676.SZ), Meinian Onehealth (002044.SZ), BUCHANG Pharmaceutical (603858.SH), ZEJING Pharmaceutical (688266.SH), Genetron Health (GTH.US), Tianshen Medical (688013.SH), Medprin (301033.SZ), HIUV New Material (688680. SH), Vazyme (688105.SH), ACROBiosystems (301080.SZ), iCarbonX, CH Biomedical, Fapon Biotech, Huajin Pharmaceutical, Haichang Biotech, Anovent Pharmaceutical, Orange Dental, Aucta, Binhui Biopharm.

About Zhangjiang Haoheng

Zhangjiang Haohang is an equity investment management company launched and established by Zhangjiang Hi-Tech in 2019, with a phase I fund size of RMB 2 billion. It focuses on technology innovation enterprises in the fields and industries of integrated circuits, biomedicine and medical devices, new generation information technology and intelligent manufacturing. Based on the core industries of Zhangjiang Science City, Zhangjiang Haohang focuses on "hard technology" industries and sectors, and uses capital to help technological innovation. At the same time, relying on the rich industrial ecology of Zhangjiang Hi-Tech, the company draws on various innovative elements and resources to provide diversified support and services such as space products, talent introduction and industrial policy support for enterprises.

About Yingke Capital

In just 10 years, Yingke Capital has become one of the top investment institutions in China, managing over RMB 50 billion assets. 90% of its entrusted funds come from financial institutions and state-owned enterprises. With the mission of “discovering the power of economic advance”, the company focuses on science and technology innovative enterprises with key core technologies in line with the national development strategy, targeting the key areas such as biomedicine and hard technology. The company adheres to the dual strategy of “investment in biomedical industry + life science industry holding" and has precisely laid out more than 100 leading companies in the whole biomedical industry chain. It is also known as an entry-level, platform-type investment institution for capital to enter the biomedical industry.